Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Avalo Therapeutics (AVTX) EBITDA Margin (2016 - 2025)

Avalo Therapeutics' EBITDA Margin history spans 12 years, with the latest figure at 23208.47% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 480275.0% year-over-year to 23208.47%; the TTM value through Dec 2025 reached 132527.12%, down 12456136.0%, while the annual FY2025 figure was 132527.12%, 12456136.0% down from the prior year.
  • EBITDA Margin reached 23208.47% in Q4 2025 per AVTX's latest filing, down from 18405.73% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 9251.81% in Q3 2024 to a low of 23208.47% in Q4 2025.
  • Average EBITDA Margin over 5 years is 3986.02%, with a median of 1341.16% recorded in 2023.
  • The largest YoY upside for EBITDA Margin was 1146706bps in 2024 against a maximum downside of -1706457bps in 2024.
  • A 5-year view of EBITDA Margin shows it stood at 8202.28% in 2021, then surged by 88bps to 988.28% in 2022, then plummeted by -36bps to 1341.16% in 2023, then tumbled by -1272bps to 18405.73% in 2024, then fell by -26bps to 23208.47% in 2025.
  • Per Business Quant, the three most recent readings for AVTX's EBITDA Margin are 23208.47% (Q4 2025), 18405.73% (Q4 2024), and 9251.81% (Q3 2024).